Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Drugs Laggard

Alexion Pharmaceuticals ( ALXN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.9%. By the end of trading, Alexion Pharmaceuticals fell $6.33 (-5.5%) to $107.93 on heavy volume. Throughout the day, 4,625,663 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1,464,700 shares. The stock ranged in price between $107.39-$115.15 after having opened the day at $115.00 as compared to the previous trading day's close of $114.26. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 35.9%, Tranzyme ( TZYM), down 6.9%, Biostar Pharmaceuticals ( BSPM), down 6.2% and Prima Biomed ( PBMD), down 6.1%.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $19.8 billion and is part of the health care sector. Shares are up 8.2% year to date as of the close of trading on Friday. Currently there are 16 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, ImmunoCellular Therapeutics ( IMUC), up 15.1%, Ambit Biosciences ( AMBI), up 11.6%, Neostem ( NBS), up 9.4% and Nymox Pharmaceutical Corporation ( NYMX), up 9.2% , were all gainers within the drugs industry with ACADIA Pharmaceuticals ( ACAD) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

Stocks Get Boost From Stronger-Than-Expected Jobs Report

Stocks Get Boost From Stronger-Than-Expected Jobs Report

Stocks Higher After U.S. Adds More Jobs Than Expected in November

Stocks Higher After U.S. Adds More Jobs Than Expected in November

Alexion Spikes Amid Report Activist Elliott Management Is Pushing for Change

Alexion Spikes Amid Report Activist Elliott Management Is Pushing for Change

Stock Futures Add to Gains After Solid November Jobs Report

Stock Futures Add to Gains After Solid November Jobs Report